NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
January 09 2024 - 8:15AM
Business Wire
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Sonoma
Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced an agreement
for the sale and marketing of Avenova®-branded products by Sonoma
in the European Union. The new products will combine Sonoma’s
existing eye product Ocudox®, which has already received a Class
IIB CE mark for sale in the European Union, with Avenova branding,
and are expected to be marketed through Sonoma’s established
European distribution network. This agreement brings together
NovaBay’s deep knowledge of eye care reflected in its Avenova brand
with Sonoma’s expertise in distributing hypochlorous acid products
overseas.
Sonoma will manufacture Ocudox by Avenova with packaging similar
to NovaBay’s Avenova products, which are the leading hypochlorous
acid-based eye care products in the U.S. Sonoma will pay NovaBay a
royalty fee based on net product sales of Ocudox by Avenova, and
Sonoma will continue to market its Ocudox product in the European
Union.
“Sonoma has built a strong and growing presence in the European
Union through a network of distributors and direct sales. We are
excited to add Avenova-branded products to our offerings. At the
same time, NovaBay has built strong brand recognition for Avenova
in the dry eye market in the United States that we believe will
resonate internationally,” said Amy Trombly, CEO of Sonoma. “Ocudox
sales in the European Union are already an important component of
our business, and we see plenty of room to expand our eye care
offerings. We are excited to partner with NovaBay on this
opportunity, which we believe will allow more people to benefit
from a quality hypochlorous acid product to aid in the treatment
and symptoms of blepharitis on the eyelid.”
“We are delighted that NovaBay will now be able to capitalize on
sales of hypochlorous acid eye care products in the European Union.
Sonoma’s CE mark includes a claim of treating blepharitis, the
inflammation that typically affects the edges of the eyelids when
tiny oil glands near the base of the eyelashes become clogged,
causing irritation and redness. We’ve long asserted that
blepharitis can lead to complications such as dry eye,” said Justin
Hall, CEO and General Counsel of NovaBay. “The EU market is
comparable in size to the U.S., giving NovaBay the opportunity to
double its sales of Avenova. NovaBay will continue to be the
exclusive seller of Avenova branded products in the U.S.”
About Ocudox Ocudox is a patented solution intended to
support the treatment of blepharitis and the daily hygiene of
eyelids and eyelashes. Ocudox cleans the eye lids, lashes and
periocular skin and assists in removing debris and microorganisms
that can cause irritation and ocular surface disease. The solution
does not contain any harmful chemicals, and there is no preparation
required prior to application and no need to rinse after use.
Ocudox is non-irritating, non-sensitizing, no stinging, no burning
and has no contraindications. Ocudox is suitable for contact lens
wearers.
About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals
is a global healthcare leader for developing and producing
stabilized hypochlorous acid (HOCl) products for a wide range of
applications, including wound, eye, oral and nasal care,
dermatological conditions, podiatry, animal health care and
non-toxic disinfectants. The company's products reduce infections,
itch, pain, scarring and harmful inflammatory responses in a safe
and effective manner. In vitro and clinical studies of HOCl show it
to have impressive antipruritic, antimicrobial, antiviral and
anti-inflammatory properties. Sonoma's stabilized HOCl immediately
relieves itch and pain, kills pathogens and breaks down biofilm,
does not sting or irritate skin and oxygenates the cells in the
area treated, thereby assisting the body in its natural healing
process. The company's products are sold either directly or via
partners in 55 countries worldwide and the company actively seeks
new distribution partners. The company has its corporate
headquarters in Boulder, Colorado and manufacturing operations in
Latin America. European marketing and sales are headquartered in
Roermond, Netherlands. More information can be found at
www.sonomapharma.com. For partnership opportunities, please contact
busdev@sonomapharma.com.
About NovaBay Pharmaceuticals, Inc.: NovaBay
Pharmaceuticals, Inc. develops and sells scientifically created and
clinically proven eyecare, skincare and wound care products.
NovaBay’s leading product Avenova® Antimicrobial Lid & Lash
Solution is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is also available directly to
consumers through online distribution channels such as Amazon.
DERMAdoctor® offers more than 30 dermatologist-developed skincare
products through the DERMAdoctor website, well-known traditional
and digital beauty retailers, and international distributors.
NovaBay also manufactures and sells effective, yet gentle and
non-irritating wound care products. The PhaseOne® brand is
distributed through commercial partners in the U.S. for
professional use only, and the NeutroPhase® brand is distributed in
China by China Pioneer Pharma Holdings, Limited. More information
about NovaBay is available here.
Forward-Looking Statements Except for historical
information herein, matters set forth in this press release are
forward-looking within the meaning of the “safe harbor” provisions
of the Private Securities Litigation Reform Act of 1995, including
statements about the commercial and technology progress and future
financial performance of Sonoma Pharmaceuticals, Inc., NovaBay
Pharmaceuticals, Inc. and their respective subsidiaries. These
forward-looking statements are identified by the use of words such
as “continue,” “develop,” “anticipate,” “expect" and “expand,”
among others. Forward-looking statements in this press release are
subject to certain risks and uncertainties inherent in the
companies’ respective businesses that could cause actual results to
vary, including such risks that regulatory clinical and guideline
developments may change, scientific data may not be sufficient to
meet regulatory standards or receipt of required regulatory
clearances or approvals, clinical results may not be replicated in
actual patient settings, protection offered by patents and patent
applications may be challenged, invalidated or circumvented by its
competitors, the available market for products will not be as large
as expected, products will not be able to penetrate one or more
targeted markets, revenues will not be sufficient to meet cash
needs or fund further development, as well as uncertainties
relative to the recent pandemic and economic development, varying
product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities,
and other risks detailed from time to time in each company’s
filings with the Securities and Exchange Commission. The
forward-looking statements in this release speak only as of this
date, and NovaBay and Sonoma each disclaims any intent or
obligation to revise or update publicly any forward-looking
statement except as required by law.
Sonoma Pharmaceuticals™ and Ocudox® are trademarks or registered
trademarks of Sonoma Pharmaceuticals, Inc. NovaBay® and Avenova®
are trademarks or registered trademarks of NovaBay Pharmaceuticals,
Inc. All other trademarks and service marks are the property of
their respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240109817350/en/
NovaBay Pharmaceuticals
Contacts At the Company
Justin Hall Chief Executive Officer and General Counsel Phone:
510-899-8800 Website: www.novabay.com Email: sales@novabay.com
Twitter: @NovaBayPharma Investor
Contact LHA Investor Relations Jody Cain Phone: 310-691-7100
Email: jcain@lhai.com Sonoma
Pharmaceuticals Contacts At the
Company Amy Trombly Chief Executive Officer and General
Counsel Website: www.sonomapharma.com Email:
busdev@sonomapharma.com Investor
Contact Email: ir@sonomapharma.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2024 to May 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From May 2023 to May 2024